Immundnz announces Eurostars project grant funding

Immundnz Ltd. is excited to announce to have been awarded a €550K Eurostars R&D grant project

together with Dutch partners GlycoMScan and TenWise. The project aims to develop a Glyco-

Immunology Service Centre.

Glycans are oligosaccharides which are linked via post-translational modifications to proteins, a

process which is called glycosylation. More than 50% of human proteins are glycosylated. Glycans have

the ability to mediate infection and disease susceptibility, and certain types can be recognized by

immunomodulatory cell surface receptors. Unraveling the role of glycosylation of immune cells and

immune cell receptors, so-called glyco-immunology, will enable therapeutics companies in fields of

cancer, neurodegeneration, inflammation and infectious diseases to find novel drug targets and

develop personalised medicines based on glyco-immunology pathways.

Immundnz is an Alderley Park based CRO, specialised in in vitro immunology research with customised

services and in-depth knowledge in immune mechanisms and protein biology to provide clients with

solutions to make better decisions in drug discovery and at the non-clinical and pre-clinical stage.

Dr Robert-Jan Lamers, Company Director at Immundnz, said: “It is anticipated that glyco-immunology

will get increasingly important in drug discovery and development in major diseases areas as changes

in glycosylation on cell surface receptors of immune cells are observed in immune-oncology, infectious

diseases such as COVID-19 and in neurodegenerative diseases like Alzheimer's Disease. To study and

understand glycosylation within the immune system, advanced models and services are required. By

partnering with the experts at GlycoMScan and TenWise, we are convinced that we have the perfect

capabilities to serve this market need with the development of a world-leading, fully-integrated Glyco-

Immunology Service Center.”